oncologydiscovery.com Oncology Discovery

oncologydiscovery.com
Title: Oncology Discovery
Keywords:
Description: Oncology Discovery Press "Enter" to skip to content Oncology Discovery open menu mobile menu toggle button twitter linkedin email Search Blog About Contact Oncology Discovery Posts The Multiple Sclero
oncologydiscovery.com is ranked 8333361 in the world (amongst the 40 million domains). A low-numbered rank means that this website gets lots of visitors. This site is relatively popular among users in the united states. It gets 50% of its traffic from the united states .This site is estimated to be worth $1,598. This site has a low Pagerank(0/10). It has 1 backlinks. oncologydiscovery.com has 43% seo score.

oncologydiscovery.com Information

Website / Domain: oncologydiscovery.com
Website IP Address: 50.87.188.225
Domain DNS Server: ns1.bluehost.com,ns2.bluehost.com

oncologydiscovery.com Rank

Alexa Rank: 8333361
Google Page Rank: 0/10 (Google Pagerank Has Been Closed)

oncologydiscovery.com Traffic & Earnings

Purchase/Sale Value: $1,598
Daily Revenue: $4
Monthly Revenue $131
Yearly Revenue: $1,598
Daily Unique Visitors 403
Monthly Unique Visitors: 12,090
Yearly Unique Visitors: 147,095

oncologydiscovery.com WebSite Httpheader

StatusCode 200
Cache-Control no-store, no-cache, must-revalidate, post-check=0, pre-check=0
Content-Type text/html; charset=UTF-8
Date Thu, 18 Aug 2016 15:21:28 GMT
Server nginx/1.10.1

oncologydiscovery.com Keywords accounting

Keyword Count Percentage

oncologydiscovery.com Traffic Sources Chart

oncologydiscovery.com Similar Website

Domain Site Title

oncologydiscovery.com Alexa Rank History Chart

oncologydiscovery.com aleax

oncologydiscovery.com Html To Plain Text

Oncology Discovery Press "Enter" to skip to content Oncology Discovery open menu mobile menu toggle button twitter linkedin email Search Blog About Contact Oncology Discovery Posts The Multiple Sclerosis Competitive Landscape The Multiple Sclerosis Competitive Landscape Published November 9, 2015 November 9, 2015 By Garrett Rhyasen, PhD Background Multiple Sclerosis (MS) is a degenerative, chronic immune-mediated disease of the central nervous system (CNS). Pathologic features of… Continue reading The Multiple Sclerosis Competitive Landscape Comments closed Trillium Therapeutics: a Pure-Play on CD47 as an Immuno-Oncology Target Trillium Therapeutics: a Pure-Play on CD47 as an Immuno-Oncology Target Published November 4, 2015 November 5, 2015 UPDATED – In the original post we mentioned that there was no published evidence demonstrating that the Inhibrx/Celgene CD47 antibody (CC-90002) does… Continue reading Trillium Therapeutics: a Pure-Play on CD47 as an Immuno-Oncology Target Comments closed Small-Molecule Strategies Aimed at Degrading Cellular Proteins Small-Molecule Strategies Aimed at Degrading Cellular Proteins Published October 15, 2015 October 15, 2015 By Garrett Rhyasen, PhD After securing a $18.25 million Series A co-led by Canaan Partners and 5AM Ventures in 2013, Arvinas, Inc., has… Continue reading Small-Molecule Strategies Aimed at Degrading Cellular Proteins Comments closed Strategies to Enhance Patient Responses to Checkpoint Inhibitors Strategies to Enhance Patient Responses to Checkpoint Inhibitors Published August 8, 2015 August 8, 2015 By Garrett Rhyasen, PhD Immuno-oncology agents targeting programmed cell death receptor-1 (PD1) and its ligand PDL1, represent a step change improvement over the… Continue reading Strategies to Enhance Patient Responses to Checkpoint Inhibitors Comments closed Epizyme Provides Update on Tazemetostat (EPZ-6438) Phase I data Epizyme Provides Update on Tazemetostat (EPZ-6438) Phase I data Published June 20, 2015 June 20, 2015 By Garrett Rhyasen, PhD Earlier today, Epizyme reported updated data from the ongoing open-label phase 1/2 trial, examining tazemetostat (EPZ-6438), a first-in-class EZH2… Continue reading Epizyme Provides Update on Tazemetostat (EPZ-6438) Phase I data Comments closed Epizyme Inc. and the Orphan Drug with Mainstream Potential Epizyme Inc. and the Orphan Drug with Mainstream Potential Published March 15, 2015 March 15, 2015 By Garrett Rhyasen, PhD Epizyme Inc. is focused on developing drugs for histone methyltransferases (HMT – also called ‘Chromatin Writers,’ written about… Continue reading Epizyme Inc. and the Orphan Drug with Mainstream Potential Comments closed Chromatin as a Cancer Target – Part III: Chromatin Readers Chromatin as a Cancer Target – Part III: Chromatin Readers Published January 4, 2015 January 4, 2015 By Garrett Rhyasen, PhD This is the final installment of a three part series, ‘Chromatin as a Cancer Target.’ If you haven’t… Continue reading Chromatin as a Cancer Target – Part III: Chromatin Readers Comments closed Posts navigation 1 2 Next Sidebar Subscribe to Oncology Discovery Enter your email address to subscribe and receive notifications of new posts. Email Address ONCOLOGY DISCOVERY Twitter FeedMy Tweets Copyright ? 2016 - ONCOLOGY DISCOVERY error: Content is protected !! Oncology Discovery Proudly powered by WordPress Theme: Period.

oncologydiscovery.com Whois

Domain Name: ONCOLOGYDISCOVERY.COM
Registrar URL: http://www.wildwestdomains.com
Registrant Name: Registration Private
Registrant Organization: Domains By Proxy, LLC
Name Server: NS1.WORDPRESS.COM
Name Server: NS2.WORDPRESS.COM
DNSSEC: unsigned
For complete domain details go to:
http://who.securepaynet.net/whoischeck.aspx?domain=ONCOLOGYDISCOVERY.COM&prog_id=391143
The data contained in this Registrar's Whois database,
while believed by the registrar to be reliable, is provided "as is"
with no guarantee or warranties regarding its accuracy. This information
is provided for the sole purpose of assisting you in obtaining
information about domain name registration records. Any use of
this data for any other purpose is expressly forbidden without
the prior written permission of this registrar. By submitting an
inquiry, you agree to these terms of usage and limitations of warranty.
In particular, you agree not to use this data to allow, enable, or
otherwise make possible, dissemination or collection of this data, in
part or in its entirety, for any purpose, such as the transmission of
unsolicited advertising and solicitations of any kind, including spam.
You further agree not to use this data to enable high volume, automated
or robotic electronic processes designed to collect or compile this data
for any purpose, including mining this data for your own personal or
commercial purposes.
Please note: the owner of the domain name is specified in the "registrant" section.
In most cases, the Registrar is not the owner of domain names listed in this database